Fundraising Fox
Aura Biosciences
NASDAQ: AURACambridge, US · Founded 2009 · Delaware corporation · 132 employees on LinkedIn · 13 known investors
Find your way into Aura Biosciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Teresa Bitetti to introduce you to Elisabet de los Pinos
You →Teresa · together at Aura Biosciences →Elisabet
Sign up to find every way you can get introduced to Aura Biosciences
- Your email: who you already know at Aura Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aura Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
Founders & leadership
Aura Biosciences was founded in 2009 by Elisabet de los Pinos, Ph.D. and Elisabet de los Pinos.
Board
Investors · 13
How we know: the S-1 prospectus · Not right? Tell us
How we know: Chiesi Ventures's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Columbus Venture Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Droia Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Medicxi's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Myelin VC's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: venBio Partners's portfolio page · Not right? Tell us
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$190.6M disclosed across 8 of 9 rounds · 2013–2026
▶$80.5MraisedApr 2021 · 41 investors · BiotechnologyRule 506(b)
- Karan TakharDirector
- Julie FederExecutive Officer
- Raj Parekh, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Giovanni Mariggi, Ph.D.Director
- David JohnsonDirector
- Offering amount
- $80.5M
- Amount sold
- $80.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2020 · 32 investors · BiotechnologyRule 506(b)
- Christian SchetterDirector
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Raj Parekh, Ph.D.Director
- Giovanni Mariggi, Ph.D.Director
- Julie FederExecutive Officer
- George Golumbeski, Ph.D.Director
- Art PappasDirector
- Joel Jean-Mairet, Ph.D.Director
- Casper BreumDirector
- Offering amount
- $17M
- Amount sold
- $10M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedApr 2019 · 36 investors · BiotechnologyRule 506(b)
- Raj Parekh, Ph.D.Director
- Casper BreumDirector
- Art PappasDirector
- Julie FederExecutive Officer
- Lewis GeffenExecutive Officer
- Giovanni Mariggi, Ph.D.Director
- Joel Jean-Mairet, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Alan E. Walts, Ph.D.Director
- Mark ChinDirector
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.3MraisedDec 2018 · 42 investors · BiotechnologyRule 506(b)
- Lewis GeffenExecutive Officer
- Casper BreumDirector
- Julie FederExecutive Officer
- Dale Pfost, Ph.D.Director
- Mark ChinDirector
- Art PappasDirector
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Joel Jean-Mairet, Ph.D.Director
- Alan E. Walts, Ph.D.Director
- Offering amount
- $42.5M
- Amount sold
- $42.3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.5MraisedNov 2017 · 38 investors · BiotechnologyRule 506(b)
- Raj Parekh, Ph.D.Director
- Michael WyzgaExecutive Officer
- Joel Jean-Mairet, Ph.D.Director
- Jose' Baselga, Ph.D.Director
- Dale Pfost, Ph.D.Director
- Alan E. Walts, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Lewis GeffenExecutive Officer
- Peter WirthDirector
- Art PappasDirector
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedMar 2015 · 21 investors · BiotechnologyRule 506(c)
- Peter B. FinnExecutive Officer
- Alan Walts, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Peter WirthDirector
- Javier GarciaDirector
- Joel Jean-Mairet, Ph.D.Director
- Art PappasDirector
- Jose Baselga, Ph.D.Director
- Dale Pfost, Ph.D.Director
- Offering amount
- $34.5M
- Amount sold
- $21M
- Minimum investment
- $25K
- Proceeds to insiders
- $1.2M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$4MraisedAug 2014 · 41 investors · BiotechnologyRule 506(c)
- Israel RuizDirector
- Peter B. FinnExecutive Officer
- Jose Baselga, Ph.d.Director
- Peter WirthDirector
- Alan WaltsDirector
- Elisabet de los Pinos, Ph.d.Executive Officer, Director
- Javier GarciaDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Minimum investment
- $25K
- Proceeds to insiders
- $500K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06c
▶$1.3MraisedJan 2014 · 16 investors · BiotechnologyRule 506(c)
- Jose Baselga, Ph.d.Director
- Israel RuizDirector
- Alan WaltsDirector
- Salvador Garcia-AtanceDirector
- Elisabet de los Pinos, Ph.d.Executive Officer, Director
- Peter B. FinnExecutive Officer
- Peter WirthDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- Proceeds to insiders
- $400.5K
- First sale
- Aug 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Aura Biosciences went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Aura Biosciences.
Frequently asked questions
- What does Aura Biosciences do?
- Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
- Who founded Aura Biosciences?
- Aura Biosciences was founded by Elisabet de los Pinos, Ph.D., Elisabet de los Pinos in 2009.
- Who are Aura Biosciences's investors?
- Aura Biosciences's investors include Advent Life Sciences, Chiesi Ventures, Columbus Venture Partners, Droia Ventures, Foresite Capital, Jazzya Investments, Medicxi, Myelin VC and 5 more.
- How much funding has Aura Biosciences raised?
- Aura Biosciences has disclosed $190.6M raised across 8 of its 9 known rounds.
- Where is Aura Biosciences headquartered?
- Aura Biosciences is headquartered in Cambridge, US.